Archimed and La Caisse have acquired blood diagnostics equipment maker Stago, the partners announced Wednesday.

Archimed Diagnostics, the diagnostics arm of healthcare-focused private-equity firm Archimed, completed the purchase alongside global investment group La Caisse through its MED Platform II fund, acquiring the company from the founding Viret family using a mix of equity and unitranche debt.

Stago, a global leader in hemostasis (blood coagulation analysis), develops and manufactures diagnostic equipment and reagents, selling into 115 countries. The company reported €550 million in revenue in 2025. Founded in 1945 and headquartered in Asnières-sur-Seine, France, Stago is described as the only pure-play hemostasis analysis company globally. Its leadership team is retaining a minority stake.

“In addition to financial muscle, Archimed and La Caisse have the operational sophistication and discretion to help us grow at a pivotal moment in our company’s history,” says incumbent Stago CEO Jean-Claude Piel, who will transition to chief of the scientific and technology monitoring committee.

Philippe Barroux, Stago’s CEO-elect, said Archimed’s diagnostics expertise is key for accelerating the efficient rollout of a major, new generation of Stago products.

“This partnership is all about reigniting innovation at Stago,” he said.

Archimed has now completed eight diagnostics acquisitions, including exits from Diesse and Eurolyser, where it reported strong performance improvements during its ownership.

“Our aim is to provide Stago with the resources it needs to accelerate global growth and to reinforce its leading position as a pure player with unrivalled expertise,” said Archimed Managing Partner Vincent Guillaumot.

Archimed plans to work closely with management to accelerate growth using its MedValue framework, focusing on international expansion, innovation and product development. The acquisition marks the 10th investment for MED Platform II, a €3.5-billion fund that closed in June 2023 and is now about 70% deployed.

“Stago is a recognized leader in blood coagulation analysis, operating in a segment we know well, and serving a mission-critical role in medical diagnostics,” said Martin Longchamps, executive vice-president and head of private equity and private credit at La Caisse.

“Our investment alongside Archimed reflects the value we place on partnerships and businesses with strong fundamentals,.”

Archimed plans to work closely with management to accelerate growth using its MedValue framework, focusing on international expansion, innovation and product development. The acquisition marks the 10th investment for MED Platform II, a €3.5-billion fund that closed in June 2023 and is now about 70% deployed.

Stago has an existing location in Mississauga, Ont. It remains to be seen whether the company will launch any manufacturing facilities in Quebec or elsewhere in Canada. But La Caisse is dedicated to expanding investment, employment and business opportunities in Quebec, suggesting that the pension-fund manager may encourage Stago to expand its operations in the province, which has a robust biomedical sector.

The purchase price was not disclosed.